Department of Endocrinology and Internal Medicine, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Dialysis Unit, 7 Navy Hospital, Gdańsk, Poland.
Front Endocrinol (Lausanne). 2023 Mar 9;13:1031188. doi: 10.3389/fendo.2022.1031188. eCollection 2022.
COVID-19 often results in generalized inflammation and affects various organs and systems. Endocrine research focused on the possible sequelae of COVID-19, with special interest given to the thyroid gland. Clinical problems such as thyroid function in non-thyroidal illness (NTI), autoimmune thyroiditis, and COVID-19-related subacute thyroiditis (SAT) quickly gained wide coverage. Thyrotoxicosis of various origins leads to the release of peripheral thyroid hormones and thyroglobulin (TG), the main glycoprotein contained within the thyroid follicular lumen. In our study, we evaluated TG levels in COVID-19-positive patients and investigated the possible relationships between TG, thyroid function tests (TFTs), and inflammatory markers. Our approach included separate subanalyses of patients who received and those who did not receive glucocorticoids (GCs). In the entire population studied, the concentration of TG tended to decrease with time (p<0.001; p1,2 = 0.025, p1,3 = 0.001, p2,3 = 0.003), and this pattern was especially clear among patients treated with GCs (p<0.001; p1,2=<0.001; p1,3=<0.001; p 2,3=<0.001). The concentration of TG differed significantly between patients treated and those not treated with GC at the second and third time points of observation (p=0.033 and p=0.001, consecutively). TG concentration did not differ between the patients with normal and abnormal TFTs. The correlations between TG, TFTs, and inflammatory markers were very limited. 19 patients had elevated TG levels, but a TFT pattern suggestive of thyrotoxicosis was not common in this group. There were no statistically significant differences between patients who met and those who did not meet the predefined combined primary endpoint.
COVID-19 常导致全身性炎症，并影响各种器官和系统。内分泌研究主要关注 COVID-19 的可能后遗症，特别关注甲状腺。临床问题如非甲状腺疾病中的甲状腺功能（NTI）、自身免疫性甲状腺炎和 COVID-19 相关亚急性甲状腺炎（SAT）迅速得到广泛关注。各种来源的甲状腺毒症导致外周甲状腺激素和甲状腺球蛋白（TG）的释放，TG 是甲状腺滤泡腔内的主要糖蛋白。在我们的研究中，我们评估了 COVID-19 阳性患者的 TG 水平，并研究了 TG、甲状腺功能检查（TFTs）和炎症标志物之间的可能关系。我们的方法包括分别分析接受和未接受糖皮质激素（GCs）治疗的患者。在整个研究人群中，TG 浓度随时间呈下降趋势（p<0.001；p1,2 = 0.025，p1,3 = 0.001，p2,3 = 0.003），这种模式在接受 GCs 治疗的患者中更为明显（p<0.001；p1,2=<0.001；p1,3=<0.001；p 2,3=<0.001）。在第二次和第三次观察时点，接受和未接受 GC 治疗的患者之间的 TG 浓度差异显著（p=0.033 和 p=0.001，连续）。TG 浓度在甲状腺功能正常和异常的患者之间无差异。TG、TFTs 和炎症标志物之间的相关性非常有限。19 名患者的 TG 水平升高，但该组中甲状腺毒症的 TFT 模式并不常见。满足和不满足预定联合主要终点的患者之间没有统计学上的显著差异。
